Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

(Schnirring, 11/12) Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug application for its COVID-flu combination and standalone flu ...

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

Major Wall Street indices closed lower on Tuesday as investors booked some profits from a post-election rally and turned ...

The three major indexes had rallied to record highs since the Nov. 5 U.S. election as ... Biotech firm Novavax dropped after ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

A slew of rules is sitting at the White House awaiting the Biden administration’s sign-off before the FDA can issue them.